OverviewStudy detailsEligibilityThings to knowResearchStudy plan
info
Simplify with AI

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

PHASE2RECRUITING

The main aim of this study is to learn how safe elritercept is and how well it is tolerated when taken alone and in combination with the JAK inhibitor, ruxolitinib. Other aims are to learn about the effects of elritercept on the signs and symptoms of MF when taken with or without ruxolitinib and to learn how elritercept affects the body, how the body processes elritercept, and the effects of elritercept on anemia when taken with or without ruxolitinib The study will also check on how safe elritercept is and how well it is tolerated.

Study details:

KER-050 is an investigational therapeutic protein designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the transforming growth factor beta (TGF-ß) family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias including anemia and thrombocytopenia in patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local study participant privacy regulations.
  2. In the opinion of the Investigator, the participant is able and willing to comply with the requirements of the protocol (e.g., all study procedures, return for follow-up visits).
  3. Male or female ≥18 years of age, at the time of signing informed consent.
  4. Eastern Cooperative Oncology Group (ECOG) performance score ≤2 (see Appendix 2).
  5. Life expectancy ≥12 months per Investigator assessment.
  6. Confirmed diagnosis of PMF (prefibrotic or overtly fibrotic) according to the 2016 World Health Organization (WHO) criteria (see Appendix 3), post-PV MF, or post-ET MF according to the 2008 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria (see Appendix 4).
  7. Anemia, defined as: 1. Having received ≥6 units of RBC transfusion for Hgb ≤8.5 g/dL in the 12 weeks prior to the planned C1D1, including ≥1 unit of RBC transfusion in the 28 days prior to C1D1; or 2. Having ≥3 evaluable Hgb measurements at <10.0 g/dL including ≥1 evaluable Hgb measurement assessed 8 to 13 weeks prior to C1D1. Participants receiving RBC transfusions but not meeting criterion 'a.' may enroll under criterion 'b.' following the below parameters: * All pre-transfusion Hgb values (defined as a Hgb assessed within the 3 days prior to a transfusion) should be recorded, and ≥1 pre-transfusion Hgb value is required. * Hgb values collected within the 28 days following a transfusion will not be considered evaluable unless qualifying as a pre-transfusion Hgb; in cases where multiple transfusions are given in succession due to poor Hgb response, only the first pre-transfusion Hgb will be considered evaluable.
  8. Arm-specific criteria: Arms 1A and 2A: 1. Previously treated with JAK inhibitor(s) and, per the Investigator, discontinued due to one of the following reasons: * Relapsed disease following treatment with JAK inhibitor(s) * Refractory to treatment with JAK inhibitor(s) * Intolerance to treatment with JAK inhibitor(s) * Participant no longer met risk/benefit ratio to continue JAK inhibitor(s) OR * Participant with prognostic score of intermediate-1 or higher per Dynamic International Prognostic Scoring System (DIPSS; see Appendix 7) and is ineligible for JAK inhibitor(s) in the opinion of the Investigator 2. Participants previously treated with JAK inhibitor(s) must have discontinued JAK inhibitor therapy ≥8 weeks before C1D1.
  9. Arms 1B and 2B: 1. Has been receiving ruxolitinib prescribed for a diagnosis of PMF (prefibrotic or overtly fibrotic), post-PV MF, or post-ET MF for ≥8 weeks prior to C1D1 and on a stable dose for ≥4 weeks prior to C1D1. In Arm 2B only, at least 10 participants should have been on ruxolitinib for <6 months prior to C1D1. 2. Meets ≥1 of the following criteria in the opinion of the Investigator: * Current ruxolitinib treatment is considered to be providing insufficient control of the disease * The participant's cytopenias are limiting the participant's ruxolitinib dose intensity * The participant's disease is symptomatic and warrants additional therapy
  10. Arm 2C (Brazil only): 1. No prior treatment with JAK inhibitor(s) and no access to JAK inhibitor therapy as determined by the Investigator 2. Platelet count ≥ 50 × 10^9/L 3. Spleen volume ≥ 450 cm3 as assessed by CT or MRI collected during the pretreatment period 4. MF-SAF-TSS meeting at least one of the following criteria during the pretreatment period: * 2 symptoms with average score ≥ 3 * Average total score ≥ 10
  11. Females of childbearing potential and sexually active males must agree to use highly effective methods of contraception as described in the protocol.

Exclusion criteria

  1. Active infection requiring parenteral antibiotic therapy within 28 days prior to C1D1 or oral antibiotics within 14 days of C1D1. Prophylactic antibiotics and/or antifungals for neutropenia are allowed.
  2. Presence of the following cardiac conditions: 1. New York Heart Association Class 3 or 4 heart failure 2. QTcF (QT interval corrected by Fridericia's formula) >500 msec on the screening or C1D1 electrocardiogram (ECG; mean of 3 measurements) 3. Uncontrolled clinically significant arrhythmia (participants with rate-controlled atrial fibrillation are not excluded) 4. Acute myocardial infarction or unstable angina pectoris ≤6 months prior to C1D1
  3. Body mass index (BMI) ≥40 kg/m2.
  4. Presence of uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite adequate treatment.
  5. History of drug or alcohol abuse (as defined by the Investigator) within the past 2 years.
  6. History of stroke, deep venous thrombosis, or arterial embolism within 6 months prior to C1D1.
  7. Major surgery within 28 days prior to C1D1. Participants must have completely recovered from any previous surgery prior to C1D1 in the opinion of the Investigator.
  8. Known positive for HIV, active infectious hepatitis B with positive viral load (hepatitis B virus [HBV] DNA), or active infectious hepatitis C with positive viral load (hepatitis C virus [HCV] RNA). Participants without a known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.
  9. Any malignancy other than PMF, post-ET MF, or post-PV MF that has not been in remission and/or has required systemic therapy including radiation, chemotherapy, hormonal therapy, or biologic therapy, within 1 year prior to C1D1. In situ cancers, squamous cell and basal cell carcinomas, and monoclonal gammopathy of unclear significance are allowed at the discretion of the Investigator.
  10. History of solid organ or hematological transplantation.
  11. History of severe allergic or anaphylactic reaction(s) or hypersensitivity to recombinant proteins or excipients in the investigational drug, or ruxolitinib for participants enrolling in Arm 1B or 2B.
  12. Diagnosis of hemolytic anemia, active bleeding, hemoglobinopathies, or congenital disorders as a cause of the participant's anemia.
  13. History of intracranial hemorrhage (any grade).
  14. NCI CTCAE Grade ≥2 bleeding events within the 3 months prior to C1D1.
  15. Receipt of an RBC or platelet transfusion for any reason(s) or combination of reasons other than underlying MF within the 12 weeks prior to C1D1. If a participant requires a transfusion for an unanticipated reason during the Pretreatment Period, a prolonged screening period may be considered after discussion with the Medical Monitor.
  16. Prior treatment with luspatercept, sotatercept, or other commercially available or investigational TGF-β inhibitors (all arms).
  17. Treatment within 28 days prior to C1D1 with: 1. ESA 2. Granulocyte colony-stimulating factor (G-CSF) 3. Granulocyte-macrophage colony-stimulating factor (GM-CSF) 4. TPO agonists 5. IMiDs (e.g., thalidomide, pomalidomide, lenalidomide) 6. Interferon 7. Hydroxyurea 8. Steroids at doses exceeding corticosteroid equivalent of 10 mg/day prednisone
  18. Newly initiated iron chelation therapy within the 8 weeks prior to C1D1. Stable doses of iron chelators are allowed if prescribed per label.
  19. Vitamin B12 and/or folate therapy initiated within 28 days prior to C1D1. Participants on stable replacement doses for ≥8 weeks and without concurrent vitamin B12 or folate deficiency are allowed.
  20. Treatment with another investigational drug or device or approved therapy for the treatment of MF or anemia in MF ≤28 days prior to C1D1, or, if the half-life of the previous product is known, within 5 times the half-life prior to C1D1, whichever is longer.
  21. For Arms 1B and 2B (participants receiving ruxolitinib), initiation of treatment with strong cytochrome P450 (CYP)3A4 inhibitors within 2 weeks prior to C1D1. Participants receiving CYP3A4 inhibitors/inducers as concomitant therapy with ruxolitinib in accordance with ruxolitinib local prescribing information may continue to receive such therapies in this study.
  22. Bone marrow aspirate blast percentage >5%. a. In the event of a non-evaluable pretreatment bone marrow aspirate expected to be due to marrow fibrosis, participants may be enrolled without bone marrow aspirate blast percentage data if all other eligibility criteria are met. Historical bone marrow data may be requested to support confirmation of diagnosis.
  23. Peripheral blood blast percentage ≥10%
  24. Platelet count <25 × 10^9/L or >450 × 10^9/L
  25. Persistent Hgb <7 g/dL despite RBC transfusions
  26. Transferrin saturation <15%
  27. Ferritin <50 ng/mL
  28. Folate <4.5 nmol/L (<2.0 pg/L)
  29. Vitamin B12 <148 pmol/L (<200 pg/mL)
  30. Estimated glomerular filtration rate <40 mL/min/1.73 m2 (as determined by the Chronic Kidney Disease Epidemiology Collaboration equation)
  31. AST or ALT >2.5 × ULN
  32. Total bilirubin >1.5 × ULN
  33. INR >1.2 × ULN, unless participant is receiving anticoagulation, in which instance the INR must fall within the participant's designated therapeutic range.
  34. Pregnant or lactating females.
  35. Any other condition not specifically noted above that, in the opinion of the Investigator or Sponsor, would preclude the participant from participating in the study.
  36. Participants who are investigational site staff members directly involved in the conduct of the study and their immediate family members, site staff members otherwise supervised by the Investigator, or participants who are Keros or contract research organization (CRO) employees directly involved in the conduct of the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

study type

Study type

TREATMENT

phase

Phase

    PHASE2

trial

Study ID

NCT05037760

Intervention or treatment

DRUG: KER-050 monotherapy

DRUG: KER-050 in combination with ruxolitinib

Conditions

  • Myelofibrosis

  • Condition: Myelofibrosis

  • DRUG: KER-050 monotherapy and other drugs

  • Concord, New South Wales, Australia and more

  • Sponsor: Takeda

Save

Share

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

Concord Hospital

Select from list below to view details:

  • Concord Hospital

    Concord, New South Wales, Australia

  • The Tweed Hospital

    Tweed Heads, New South Wales, Australia

  • Flinders Medical Centre

    Woodville South, South Australia, Australia

  • St. Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

Loading map...

Who is running the clinical trial?

T

Takeda

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Arm 1A: Elritercept
  • Participants with anemia who have discontinued Janus Kinase (JAK) inhibitor(s) or are intolerant or ineligible for JAK inhibitor(s) will be administered escalating doses of elritercept, starting at 0.75 milligrams per kilograms (mg/kg) followed by 1.5 mg/kg and 4.5 mg/kg subcutaneously (SC), every 4 weeks for 13 cycles for a total Treatment Period of 52 weeks. Each cycle is 28 days.
Drug: Elritercept
    EXPERIMENTAL: Arm 1B: Elritercept + Ruxolitinib
    • Participants with anemia who have been receiving ruxolitinib for ≥8 weeks prior to Cycle 1 Day 1 (C1D1) and are on a stable dose for ≥4 weeks prior to C1D1 will be administered escalating doses of elritercept, starting at 0.75 mg/kg and followed by 1.5 mg/kg and 4.5 mg/kg, SC, every 4 weeks for 13 cycles in combination with ruxolitinib therapy for a total Treatment Period of 52 weeks. Each cycle is 28 days.
    Drug: Elritercept, Drug: Ruxolitinib
      EXPERIMENTAL: Arm 2A: Elritercept
      • Participants with with anemia who have discontinued JAK inhibitor(s) or are intolerant or ineligible for JAK inhibitor(s) will be administered elritercept, 3.75 mg/kg, SC, every 4 weeks for 13 cycles for a total Treatment Period of 52 weeks. Each cycle is 28 days.
      Drug: Elritercept
        EXPERIMENTAL: Arm 2B: Elritercept + Ruxolitinib
        • Participants with anemia who have been receiving ruxolitinib for ≥8 weeks prior to C1D1 and are on a stable dose for ≥4 weeks prior to C1D1 will be administered elritercept, 3.75 mg/kg, SC, every 4 weeks for 13 cycles in combination with ruxolitinib therapy for a total Treatment Period of 52 weeks. Each cycle is 28 days.
        Drug: Elritercept, Drug: Ruxolitinib
          EXPERIMENTAL: Experimental: Arm 2C: Elritercept (Brazil Only)
          • Participants from Brazil with anemia who have received no prior treatment with JAK inhibitor(s) and have no access to JAK inhibitor therapy will be administered elritercept, 3.75 mg/kg, SC, every 4 weeks for 13 cycles for a total Treatment Period of 52 weeks. Each cycle is 28 days.
          Drug: Elritercept
            EXPERIMENTAL: Long-Term Extension
            • Participants from Arms 1A, 1B, 2A, 2B and 2C benefiting from the continued elritercept treatment as a monotherapy or in combination with ruxolitinib can continue to receive elritercept in this long-term extension phase until elritercept becomes commercially available or until elritercept is no longer being developed for the treatment of MF.
            Drug: Elritercept, Drug: Ruxolitinib

              What is the study measuring?

              Primary Outcome

              MeasureDescriptionTime Frame
              Incidence of adverse events (Safety and Tolerability)Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs)52 Weeks

              Secondary Outcome

              MeasureDescriptionTime Frame
              Evaluate the effect of KER-050 on progression to AML or accelerated MF• Proportion of participants with progression to AML52 weeks
              Evaluate the effect of KER-050 on progression to AML or accelerated MF• Proportion of participants with progression to accelerated MF52 weeks
              Evaluate the effect of KER-050 on anemiaSubgroup of participants with anemia requiring RBC Transfusions • Proportion of participants with RBC transfusion independence over a period of \>12 consecutive weeks within the first 24 weeks of the study24 weeks
              Evaluate the effect of KER-050 on anemiaSubgroup of participants with anemia requiring RBC Transfusions • Proportion of participants with decrease in number of RBC transfusions from baseline over a period of \>12 consecutive weeks within the first 24 weeks of the study24 weeks
              Evaluate the effect of KER-050 on anemiaSubgroup of transfusion-independent participants • Proportion of participants with mean hemoglobin increase ≥1.5 g/dL from baseline over a period of \>12 consecutive weeks within the first 24 weeks of the study24 weeks
              Evaluate the effect of KER-050 on anemiaSubgroup of transfusion-independent participants • Proportion of participants with mean hemoglobin increase ≥2.0 g/dL from baseline over a period of \>12 consecutive weeks within the first 24 weeks of the study24 weeks
              Evaluate the effect of KER-050 on MF disease manifestations and symptoms· Proportion of participants with improvement in the Myelofibrosis Symptom Assessment Form Total Symptom Score (MF-SAF-TSS) where 1 = absent and 100 = worst imaginable, of ≥50% from baseline at Week 2452 weeks
              Evaluate the effect of KER-050 on MF disease manifestations and symptoms· Proportion of participants with decrease in spleen volume of ≥35% from baseline as measured by CT/MRI at Week 24 (excluding participants' status post splenectomy or splenic irradiation)52 weeks
              Evaluate the PK profile of KER-050• Plasma concentrations of KER-05052 weeks
              Evaluate the PK profile of KER-050• Cmax52 weeks
              Evaluate the PK profile of KER-050Tmax52 weeks
              Evaluate the PK profile of KER-050AUC0-last (C1 only)Through Cycle 1 (each cycle is 28 days)
              Evaluate the PK profile of KER-050• Cmin52 weeks
              Evaluate the PK profile of KER-050Rac52 weeks
              Evaluate the effect of KER-050 on erythropoiesisMeasure change from baseline of red cell parameters • reticulocyte count52 weeks
              Evaluate the effect of KER-050 on erythropoiesisMeasure change from baseline of red cell parameters •Hgb52 weeks
              Evaluate the effect of KER-050 on erythropoiesisMeasure change from baseline of red cell parameters • MCV52 weeks
              Evaluate the effect of KER-050 on erythropoiesisMeasure change from baseline of red cell parameters •MCH52 weeks
              Evaluate the effect of KER-050 on erythropoiesisMeasure change from baseline of red cell parameters • Reticulocyte cell Hgb52 weeks
              Are you running this trial?If you're a clinic or sponsor, you can claim this study.
              Claim this trial

              References

              Clinical Trials Gov: A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

              Other trials to consider

              Loading suggested trials...

              Top searched conditions

              Breast CancerLung CancerType 2 DiabetesDermatitisAlzheimersParkinsonsLupusCrohn’s DiseaseAsthmaHypertensionCOPDMultiple SclerosisOsteoarthritisHIV/AIDSPsoriasisStrokeObesityProstate CancerDepressionCardiovascular